Page last updated: 2024-10-30

labetalol and Body Weight

labetalol has been researched along with Body Weight in 16 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)."9.06Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990)
"Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies."7.80Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014)
"We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig."7.71Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002)
"Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta- adrenoceptor blockade induced by oral labetalol treatment for 2 months."7.66Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1980)
"Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months."7.66Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1979)
"Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)."5.06Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990)
"Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies."3.80Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014)
"We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig."3.71Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002)
"Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta- adrenoceptor blockade induced by oral labetalol treatment for 2 months."3.66Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1980)
"Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months."3.66Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1979)
" In all the drug-treated groups, increase in salivation was observed from immediately to 15 minutes after dosing through the treatment period."1.26[On the subacute toxicity of labetalol (AH5158): a combined alpha-and beta-adrenoceptor blocking agent (author's transl)]. ( Fujiwara, S; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1980)
" In all the drug-treated groups, increase in salivation was observed from immediately after to 15 minutes after dosing through treatment period."1.26[On the chronic toxicity of labetalol (AH-5158); a combined alpha-and beta-adrenoceptor-blocking agent (author's transl)]. ( Fujiwara, S; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1981)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19909 (56.25)18.7374
1990's5 (31.25)18.2507
2000's1 (6.25)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fischer, JH1
Sarto, GE1
Hardman, J1
Endres, L1
Jenkins, TM1
Kilpatrick, SJ1
Jeong, H1
Geller, S1
Deyo, K1
Fischer, PA1
Rodvold, KA1
Hunyor, SN1
Bauer, GE1
Ross, M1
Larkin, H1
Kornerup, HJ3
Pedersen, EB3
Pedersen, A3
Pedersen, G3
Christensen, NJ3
Shimpo, K2
Yokoi, Y2
Fujiwara, S2
Togashi, H2
Tanabe, T2
Pape, D1
Goineau, S1
Guillo, P1
Ramée, MP1
Bellissant, E1
Weidmann, P1
De Chătel, R1
Ziegler, WH1
Flammer, J1
Reubi, F1
Prichard, BN1
Boakes, AJ1
Hernández, R1
Bolli, P1
Waal-Manning, J1
Wood, AJ1
Simpson, FO1
Erdtsieck-Ernste, EB1
Feenstra, MG1
Botterblom, MH1
De Barrios, J1
Boer, GJ1
Selan, F1
McCullough, CB1
Black, HE1
McGrath, BP1
Matthews, PG1
Louis, W1
Howes, L1
Whitworth, JA1
Kincaid-Smith, PS1
Fraser, I1
Scheinkestel, C1
MacDonald, G1
Rallings, M1
Gonzalez, ER1
Peterson, MA1
Racht, EM1
Ornato, JP1
Due, DL1
Abate, MA1
Neely, JL1
Layne, RD1
D'Alessandri, R1

Trials

7 trials available for labetalol and Body Weight

ArticleYear
Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects.
    Australian and New Zealand journal of medicine, 1980, Volume: 10, Issue:2

    Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Therapy, Combination; Ethanolamines; Female; Humans;

1980
Labetalol in the treatment of severe essential hypertension: relationship between arterial blood pressure, plasma catecholamines, plasma renin activity, plasma aldosterone and body weight.
    Acta medica Scandinavica. Supplementum, 1979, Volume: 625

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Blood Pressure;

1979
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.
    The American journal of cardiology, 1978, Volume: 41, Issue:3

    Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Volume; Body Weight; Chlorthalidone; Clinical Trials

1978
Experience with labetalol in hypertension.
    British journal of clinical pharmacology, 1976, Volume: 3, Issue:4 Suppl 3

    Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Diuretics; Drug Evaluation; Drug

1976
Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension.
    Journal of cardiovascular pharmacology, 1990, Volume: 16, Issue:5

    Topics: Adult; Aged; Blood Pressure; Body Weight; Captopril; Double-Blind Method; Drug Therapy, Combination;

1990
Dose-response evaluation of oral labetalol in patients presenting to the emergency department with accelerated hypertension.
    Annals of emergency medicine, 1991, Volume: 20, Issue:4

    Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Dose-Response

1991
Interaction of indomethacin and sulindac with labetalol.
    British journal of clinical pharmacology, 1991, Volume: 31, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Chlorides; Drug Interactions; Humans

1991

Other Studies

9 other studies available for labetalol and Body Weight

ArticleYear
Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.
    Clinical pharmacokinetics, 2014, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Antihypertensive Agents; Body Weight; Dose-Response Relationship, Drug; Female; G

2014
Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension.
    Postgraduate medical journal, 1980, Volume: 56 Suppl 2

    Topics: Adult; Aged; Aldosterone; Body Weight; Epinephrine; Ethanolamines; Female; Humans; Hypertension; Lab

1980
[On the subacute toxicity of labetalol (AH5158): a combined alpha-and beta-adrenoceptor blocking agent (author's transl)].
    The Journal of toxicological sciences, 1980, Volume: 5, Issue:4

    Topics: Animals; Body Weight; Drinking; Ethanolamines; Female; Kidney; Labetalol; Liver; Male; Muscles; Pota

1980
[On the chronic toxicity of labetalol (AH-5158); a combined alpha-and beta-adrenoceptor-blocking agent (author's transl)].
    The Journal of toxicological sciences, 1981, Volume: 6, Issue:1

    Topics: Animals; Body Weight; Drinking; Eating; Ethanolamines; Female; Labetalol; Male; Organ Size; Rats

1981
Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig.
    Journal of cardiovascular pharmacology, 2002, Volume: 39, Issue:5

    Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Valve Stenosis; Body Weight; Disease Models, Ani

2002
Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.
    European journal of clinical pharmacology, 1979, Volume: 16, Issue:5

    Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Catecholamines; Epinephrine; Ethanolamines; F

1979
Long-term treatment of hypertension with labetalol.
    British journal of clinical pharmacology, 1979, Volume: 8, Issue:Suppl 2

    Topics: Adult; Aged; Blood Cell Count; Blood Pressure; Body Weight; Drug Tolerance; Ethanolamines; Female; H

1979
Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol.
    British journal of pharmacology, 1992, Volume: 105, Issue:1

    Topics: Animals; Animals, Newborn; Biogenic Amines; Body Weight; Brain; Labetalol; Organ Size; Propranolol;

1992
Preclinical safety evaluation of dilevalol (SCH 19927), an antihypertensive agent, in the rat.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1992, Volume: 18, Issue:3

    Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Body Weight; Drug Evaluation, Preclinical

1992